Global S&T Development Trend Analysis Platform of Resources and Environment
DOI | 10.1038/s41467-018-06036-0 |
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer | |
Wu, Xiujuan; Tang, Peng; Li, Shifei; Wang, Shushu; Liang, Yueyang; Zhong, Ling; Ren, Lin; Zhang, Ting; Zhang, Yi | |
2018-02-26 | |
发表期刊 | NATURE COMMUNICATIONS
![]() |
ISSN | 2041-1723 |
出版年 | 2018 |
卷号 | 9 |
文章类型 | Article |
语种 | 英语 |
国家 | Peoples R China |
英文摘要 | Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects. |
领域 | 资源环境 |
收录类别 | SCI-E |
WOS记录号 | WOS:000426049100005 |
WOS关键词 | PATHOLOGICAL COMPLETE RESPONSE ; ARTERIAL CHEMOEMBOLIZATION ; ANTITUMOR-ACTIVITY ; CHEMOTHERAPY ; DOCETAXEL ; CARBOPLATIN ; EPIRUBICIN ; PACLITAXEL ; CISPLATIN ; DOXORUBICIN |
WOS类目 | Multidisciplinary Sciences |
WOS研究方向 | Science & Technology - Other Topics |
URL | 查看原文 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/203985 |
专题 | 资源环境科学 |
作者单位 | Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China |
推荐引用方式 GB/T 7714 | Wu, Xiujuan,Tang, Peng,Li, Shifei,et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer[J]. NATURE COMMUNICATIONS,2018,9. |
APA | Wu, Xiujuan.,Tang, Peng.,Li, Shifei.,Wang, Shushu.,Liang, Yueyang.,...&Zhang, Yi.(2018).A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.NATURE COMMUNICATIONS,9. |
MLA | Wu, Xiujuan,et al."A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer".NATURE COMMUNICATIONS 9(2018). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论